Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

Atwood & Palmer Inc. slightly reduced its stake in Regeneron Pharmaceuticals, selling 1,709 shares in Q1 while still holding ...

TB Alternative Assets Ltd. has joined the biotech investing party by purchasing 3,158 shares of Regeneron Pharmaceuticals ...

If you like what we do here, forward this email to a friend. They can get this newsletter every week through a STAT+ subscription, which is 50% off through next Monday.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to ...

( NewsNation) — The interim CEO of 23andMe will face questions from lawmakers Wednesday about the DNA company’s data privacy amid a multistate lawsuit about its customers’ genetic data. The Senate ...

The genetic-testing company, which collected DNA data from users, is for sale in bankruptcy court. Now, 27 states and the ...

A hearing this week marked a critical juncture in the national conversation about the intersection of biotechnology, privacy, ...

Lawmakers raised questions and concerns about the sale of genetic-testing company 23andMe during a hearing on Tuesday.